



Published in final edited form as:

Nature. 2012 October 25; 490(7421): 508–513. doi:10.1038/nature11558.

## Structure of the agonist-bound neurotensin receptor

Jim F. White<sup>1</sup>, Nicholas Noinaj<sup>2</sup>, Yoko Shibata<sup>3,\*</sup>, James Love<sup>4,\$</sup>, Brian Kloss<sup>4</sup>, Feng Xu<sup>1,%</sup>, Jelena Gvozdenovic-Jeremic<sup>1,#</sup>, Priyanka Shah<sup>1</sup>, Joseph Shiloach<sup>5</sup>, Christopher G. Tate<sup>3</sup>, and Reinhard Grisshammer<sup>1,\*\*</sup>

<sup>1</sup>Membrane Protein Structure Function Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA

<sup>2</sup>Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA

<sup>3</sup>MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK

<sup>4</sup>Protein Production Facility of the New York Consortium on Membrane Protein Structure, New York Structural Biology Center, New York 10027, NY, USA

<sup>5</sup>Biotechnology Core Lab, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA

### Summary

Neurotensin (NT) is a 13 amino acid peptide that functions as both a neurotransmitter and a hormone through activation of the neurotensin receptor NTS1, a G protein-coupled receptor (GPCR). In the brain, NT modulates activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake, and in the gut NT regulates a range of digestive

---

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*\*Correspondence and requests for materials should be addressed to RG ([rkgriss@helix.nih.gov](mailto:rkgriss@helix.nih.gov)).

\*Current Address: MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

\$Current address: Albert Einstein College of Medicine, Price Center, New York 10461, NY, USA

%Current Address: College of Pharmacy, State Key Laboratory of Medicinal Chemical Biology and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, People's Republic of China

#Current address: National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA

Supplementary Information is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

### Author contributions

JFW characterized various NTS1 constructs by ligand binding and G-protein assays, tested NTS1 mutants for stability, and purified NTS1 for crystallization. NN collected diffraction data and solved the structure. YS performed alanine scanning mutagenesis and tested NTS1 mutants for stability, and CGT was responsible for the mutagenesis strategy. JL and BK explored and performed the automation of alanine scanning mutagenesis. FX performed crystallization experiments and stability tests. JG-J and PS did alanine scanning and molecular biology on NTS1. JS performed large-scale fermentation. RG performed crystallization experiments, assisted with data collection and was responsible for the overall project strategy. The manuscript was written by RG and CGT.

### Author information

Coordinates and structure factors for NTS1-GW5-T4L are deposited in the Protein Data Bank (accession code 4GRV). Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Readers are welcome to comment on the online version of this article at [www.nature.com/nature](http://www.nature.com/nature).

processes. Here we present the structure at 2.8 Å resolution of NTS1 in an active-like state, bound to NT<sub>8-13</sub>, the C terminal portion of NT responsible for agonist-induced activation of the receptor. The peptide agonist binds to NTS1 in an extended conformation nearly perpendicular to the membrane plane with the C-terminus oriented towards the receptor core. Our findings provide the first insight into the binding mode of a peptide agonist to a GPCR and may support the development of non-peptide ligands that could be useful in the treatment of neurological disorders, cancer and obesity.

---

## Introduction

Neurotensin (NT) is a short peptide that is found in the nervous system and in peripheral tissues<sup>1</sup>. NT shows a wide range of biological activities and plays important roles in Parkinson's disease and the pathogenesis of schizophrenia, the modulation of dopamine neurotransmission, hypothermia, antinociception and in promoting the growth of cancer cells<sup>2-6</sup>. Three neurotensin receptors have been identified. NTS1 (ref.<sup>7</sup>) and NTS2 (ref.<sup>8</sup>) belong to the class A GPCR family, whereas NTS3 is a member of the sortilin family with a single transmembrane domain<sup>9</sup>. Most of the known effects of NT are mediated through NTS1 (ref.<sup>5</sup>) which signals preferentially *via* the Gq protein. Many aspects of ligand binding to NTS1 have been addressed by mutagenesis and modeling<sup>10-12</sup> but the details of ligand binding remains poorly understood at the molecular level. This has limited the rational design of compounds targeting NTS1 for therapeutic purposes<sup>5</sup> in the absence of structural information on NTS1 in complex with agonist or antagonist.

Recent progress in elucidating GPCR structures in complex with either small-molecule antagonists, agonists or in complex with a heterotrimeric G protein has provided detailed molecular insights into GPCR function (reviewed in refs.<sup>13-15</sup>). However, the majority of receptor structures are of GPCRs belonging to the  $\alpha$  group of class A (ref.<sup>16</sup>), which characteristically bind small endogenous agonists deep within the transmembrane core. NTS1 belongs to a large family of peptide receptors in the  $\beta$  group of class A GPCRs<sup>16</sup> (Fig. S1) that includes receptors for substance P, cholecystokinin, neuropeptide Y, endothelin and oxytocin. These peptide receptors bind agonists of a wide range of sizes, from a few amino acid residues to over 60. Current structural information on peptide receptors is limited to representatives of the  $\gamma$  group of class A GPCRs<sup>16</sup>, namely the opioid receptors<sup>17-20</sup> and a chemokine receptor<sup>21</sup>, all bound to non-peptidic drug-like antagonists. The CXCR4 receptor has also been crystallized in the presence of a cyclic peptide antagonist<sup>21</sup>. Although the structural understanding of peptide receptors has advanced, structures of peptide GPCRs from the  $\beta$  group have not yet been reported. In addition, no structures have been presented of a GPCR bound to a peptide agonist and only the structures of rhodopsin<sup>22,23</sup> and the adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R)<sup>24</sup> have been determined bound to endogenous agonists. Here we present the crystal structure of *Rattus norvegicus* NTS1 from the  $\beta$  GPCR subfamily bound to the C terminal portion (NT<sub>8-13</sub>) of the endogenous agonist NT.

## Crystallization and structure determination of NTS1 in an agonist-bound state

Wild-type NTS1 is unstable in detergent solution and hence a difficult target for structural studies, particularly in the agonist-bound state which is generally thought to be less stable than the antagonist-bound state<sup>25</sup>. The first step was therefore to stabilize NTS1 using the strategy of conformational thermostabilization<sup>26</sup>. Previous work had generated a thermostable mutant of NTS1, but the purified receptor was found unsuitable for crystallization, possibly because the receptor contained mutations that were selected in the unliganded state<sup>27</sup>. NTS1 was therefore thermostabilized in the presence of the agonist NT through the inclusion of 6 stabilizing mutations (mutant NTS1-GW5; A86L<sup>1.54</sup>, E166A<sup>3.49</sup>, G215A<sup>ECL2</sup>, L310A<sup>6.37</sup>, F358A<sup>7.42</sup> and V360A<sup>7.44</sup>; superscripts are the Ballesteros-Weinstein numbers<sup>28</sup>) (Fig. S2, Table S1). Pharmacological characterization of NTS1-GW5 (Fig. S3, Table S2, Supplementary Discussion) showed that the affinity for the agonist NT was similar to that of the wild-type receptor, but that the apparent affinity for the neutral antagonist SR48692 and the sensitivity to Na<sup>+</sup> ions was lower. In G protein coupling assays, NTS1-GW5 did not catalyze nucleotide exchange at Gαq in response to NT (Fig. S3), suggesting that the stabilizing mutations may have limited the ability to propagate the agonist-induced conformational change at the ligand binding pocket to the re-arrangement of the intracellular face of the receptor required for G protein binding and activation.

For crystallization of NTS1-GW5, T4 lysozyme (T4L) was engineered into intracellular loop 3 (ICL3) to improve the probability of obtaining well-diffracting crystals<sup>29</sup>. NTS1-GW5-T4L was expressed in insect cells using the baculovirus expression system, solubilized and purified in lauryl maltose neopentyl glycol and crystallized using the lipidic cubic phase methodology<sup>30</sup>. Diffraction data were collected to 2.8 Å resolution from a single crystal and used to determine the structure by molecular replacement (Table S3, Fig. S4, Fig. S5). The final model of NTS1-GW5-T4L, refined to R/R<sub>free</sub> values of 0.23/0.28, includes 454 residues, 2 Hepes molecules, 23 H<sub>2</sub>O molecules and the agonist ligand NT<sub>8-13</sub>.

### Overall structure of NTS1-GW5-T4L

The receptor core has seven transmembrane helices (TM1-TM7) (Fig. 1, Fig. S6), as expected, but there was no density corresponding to amphipathic helix 8 at the C-terminus of the receptor. Helix 8 has been observed in all GPCR structures except for the chemokine receptor CXCR4 (ref.<sup>21</sup>), so the absence of helix 8 in the structure of NTS1-GW5-T4L could be because either NTS1 *in vivo* does not possess H8 or this is the result of a crystallization artifact. On the intracellular side, TM7 is elongated by three helical turns beyond the conserved NP<sup>7.50</sup>XXY<sup>7.53</sup> motif, whilst other GPCRs have only one helical turn. This extension of TM7 is associated with the intracellular end of TM6 through hydrogen bonds between the side chain atoms of N375 and Q378 to the backbone carbonyl oxygen of A302<sup>6.29</sup> (Fig. S7).

Of the intracellular loops in NTS1, ICL1 was disordered (K93-Q96), ICL3 was disrupted through insertion of T4L and only ICL2 showed density for a structural element, a short π-helix (Fig. 1). ICL2 is thought to be important for G protein coupling and the short helix in

NTS1 is similar to those observed in identical positions in both the inactive state<sup>31</sup> and in active states<sup>32,33</sup> of  $\beta$ -adrenergic receptors ( $\beta$ ARs). In the  $\beta_1$ -adrenergic receptor ( $\beta_1$ AR)<sup>31</sup>, the helix in ICL2 is stabilized by the interaction of a tyrosine residue in the middle of the helix that forms a hydrogen bond with the aspartate residue of the conserved D/ER<sup>3,50</sup>Y sequence in TM3. In NTS1, K178 in the middle of the  $\pi$ -helix in ICL2 may perform a similar function, although its side chain is disordered, probably because the stabilizing mutation E166A<sup>3,49</sup> prevents the formation of the salt bridge. The extracellular surface of NTS1 is composed of 3 short extracellular loops (ECL1, 2 and 3) and the N-terminal residues N52-D60 that extend across the receptor to form one side of the ligand binding pocket (see below). The longest loop is ECL2, which contains two short antiparallel  $\beta$ -strands that are linked to TM3 by a disulphide bond between the conserved residues C142<sup>3,25</sup> and C225<sup>ECL2</sup>. These  $\beta$ -strands are characteristic of all the peptide GPCR structures determined so far.

NTS1-GW5-T4L contains six thermostabilizing mutations and none of these residues are in the NT binding pocket (Fig. 1). Three of these mutations may directly affect the equilibrium between inactive and active states of NTS1. The mutation F358A<sup>7,42</sup> is located at the kink in TM7, with the alanine side chain pointing into the receptor core, and the F358A mutant is known to be constitutively active<sup>34</sup>. The mutation E166A<sup>3,49</sup> is in the conserved D/ER<sup>3,50</sup>Y motif in TM3 and will prevent the formation of the intrahelical salt bridge with R167<sup>3,50</sup>, thus facilitating the transition to the active state<sup>35,36</sup> by allowing R167<sup>3,50</sup> to interact with N257<sup>5,58</sup>. The R167-N257 interaction may be promoted by the L310A<sup>6,37</sup> mutation through decreasing the size of the side chain. The reasons for the thermostabilizing effect of the A86L<sup>1,54</sup>, V360A<sup>7,44</sup> and G215A<sup>ECL2</sup> mutations are not obvious, although it is interesting that an alanine residue<sup>37</sup> is found in human NTS1 (Fig. S8) at the position equivalent to G215 in rat NTS1.

### NTS1-GW5 is in an active-like conformation

Upon agonist binding, a GPCR undergoes conformational changes that ultimately allow binding and activation of a G protein at the intracellular surface of the receptor. Agonist-induced conformational changes in the ligand binding pocket are largely receptor specific and thought to be relatively small, leading to larger conformational changes in the intracellular half of the receptor<sup>13</sup>. There are no reported structures of NTS1 in an inactive conformation, so we are unable to discuss agonist-specific conformational changes in the ligand binding pocket. However, it is possible to compare the NTS1 structure to the inactive and active conformations of rhodopsin and  $\beta_2$ AR. This allows an assessment of the overall conformation of NTS1 and, in addition, the rotamer conformations of mechanistically important residues that show characteristic interactions depending on whether the receptor is in an inactive or active state. These comparisons suggest that NTS1 is in an active-like state.

One of the major conformational changes occurring during the transition from the inactive to an active state is an outward tilt of TM6 at the intracellular face of the GPCR. The extent of movement of TM6 upon activation is 6 Å for rhodopsin and 11-14 Å for  $\beta_2$ AR<sup>32</sup>, with TM6 of NTS1 in a position similar to that seen for the active states of rhodopsin<sup>22,38</sup> (Fig. 2). The distance between the C $\alpha$  atoms of R<sup>3,50</sup> and E<sup>6,30</sup> change upon activation from 9 Å to 15 Å

in rhodopsin<sup>22,39</sup>, and from 11 Å to 19 Å in  $\beta_2$ AR<sup>32,40</sup>. The equivalent distance in NTS1 is 14 Å.

Other features of NTS1 are also remarkably similar to those found in the active conformations of rhodopsin and  $\beta_2$ AR. In inactive receptor conformations, R<sup>3.50</sup> of the D/ERY motif forms an intrahelical salt bridge with D/E<sup>3.49</sup>, that is, for example, present in the inactive structure of the nociceptin/orphanin FQ receptor (NOP)<sup>19</sup> (Fig. 3), which is the closest structural homologue of NTS1 among peptide receptors. Upon activation, the D/E<sup>3.49</sup>-R<sup>3.50</sup> salt bridge is broken and R<sup>3.50</sup> re-orientes to form an interhelical hydrogen bond with the conserved tyrosine residue Y<sup>5.58</sup> linking TM3 and TM5 (ref.<sup>13</sup>). In NTS1, the R167<sup>3.50</sup> side chain is hydrogen bonded to N257<sup>5.58</sup> that interacts with the conserved residue S164<sup>3.47</sup> (Fig. 3) stabilizing TM5 in an active-like orientation<sup>35</sup>. In addition, Y369<sup>7.53</sup> of the highly conserved NP<sup>7.50</sup>xxY<sup>7.53</sup> motif occupies space within the helical bundle as seen for Y<sup>7.53</sup> in the active states of rhodopsin and  $\beta_2$ AR (Fig. 3). In contrast to the active rhodopsin and  $\beta_2$ AR, Y369<sup>7.53</sup> in NTS1 does not pack against R167<sup>3.50</sup> suggesting that N257<sup>5.58</sup> has a greater contribution to the active state stabilization than Y369<sup>7.53</sup> (ref.<sup>35</sup>).

Comparison of the NTS1 structure with rhodopsin and  $\beta_2$ AR suggests that it is in an active-like state, which implies that it may couple effectively to G proteins. NTS1-GW5-T4L, as expected, does not couple to G protein (Fig. S3), because T4L replaces most of ICL3 that is essential for G protein binding and sterically blocks access to the intracellular surface of the receptor. Surprisingly, NTS1-GW5 that contains the wild type ICL3 also does not catalyze nucleotide exchange at G $\alpha_q$  in response to NT (Fig. S3). This may be a consequence of the extended region of TM7 on the intracellular surface forming an interhelical contact with TM6 (Fig. S7). This appears to occlude the cavity at the intracellular face of the receptor where the C-terminal portion of the G $\alpha$  protein binds to fully active receptors<sup>22,23,32,38</sup>. Thus, although the structure of NTS1 contains many features of an active receptor it is likely that the intracellular surface of the receptor does not represent the structure of fully active NTS1.

## The NT<sub>8-13</sub> binding site

NTS1-GW5-T4L was co-crystallized with NT<sub>8-13</sub>, which has higher potency and efficacy than full-length NT<sup>10,41</sup>, although it does not exist *in vivo*. NTS1 also binds the NT-related hexapeptide neuromedin N (NN) that is produced along with NT during proteolytic processing of the proNT precursor<sup>5</sup>. The amino acid sequence of NN (KIPYIL) is similar to NT<sub>8-13</sub> (RRPYIL). Potent NT analogues that can cross the blood-brain barrier (e.g. derivatives of RKPWLL) can also be synthesized (see ref.<sup>5</sup>). The similarity of these agonists to NT<sub>8-13</sub> suggests that they all bind in a similar manner. There is charge complementarity between NT<sub>8-13</sub> and its binding pocket, with the positive-charged arginine side chains of NT<sub>8-13</sub> adjacent to the electronegative rim of the binding site, and the C-terminus of NT<sub>8-13</sub> is predicted to form a salt bridge with R327<sup>6.54</sup> (Fig. 4, Table S4). There are also extensive van der Waals interactions between NT<sub>8-13</sub> and the receptor along with hydrogen bonds and a salt bridge (Table S4, Table S5, Fig. S9). It is striking that only 3 out of 8 hydrogen bonds

are made between the side chains of NT<sub>8-13</sub> and the receptor, with the bulk of receptor-ligand contacts being van der Waals interactions.

The ligand binding pocket for NT<sub>8-13</sub> is composed of amino acid residues in the N-terminus, the three extracellular loops (ECL1-ECL3) and six transmembrane  $\alpha$ -helices (TM2-TM7), with the greatest number of ligand-receptor contacts from residues in ECL2, ECL3, TM6 and TM7 (Table S5). The binding pocket is wide open on the extracellular surface of NTS1 (Fig. 4, Fig. S10) with density for NT<sub>8-13</sub> clearly discernable from a difference electron map (Fig. S11), but we believe that radiation damage during data collection has resulted in reduced density for the C-terminal carboxylate group (Fig. S12). The extended conformation of NT<sub>8-13</sub> in the crystal structure is in good agreement with that of NT<sub>8-13</sub> bound to wild-type NTS1 analyzed by solid-state NMR<sup>42</sup> (Fig. S13). The overall shape of the NTS1 ligand binding pocket is narrower than that observed in the other peptide receptors<sup>17-21</sup> due to an inward shift of the extracellular regions of TM2 and TM6 (Fig. S14), probably as a result of the pronounced kink in TM2 at A120<sup>2,57</sup> and a change in tilt of TM6. At the extracellular surface, the NT<sub>8-13</sub> binding pocket is partially capped by the ECL2  $\beta$ -hairpin and the proximal end of the receptor N-terminus. NTS1 has been subjected to extensive site-directed mutagenesis studies to define ligand-receptor interactions (see Supplementary Discussion) and there is excellent agreement between those data and the structure of NTS1.

There is a striking difference between the binding mode of NT<sub>8-13</sub> in NTS1 with the binding of agonists in rhodopsin,  $\beta_1$ AR and A<sub>2A</sub>AR (Fig. 5). The agonist-specific interactions made by isoprenaline in  $\beta_1$ AR (ref.<sup>43</sup>) and adenosine in A<sub>2A</sub>AR (ref.<sup>24</sup>) all occur at a similar depth in the receptor with respect to the extracellular surface as retinal in rhodopsin<sup>22,23</sup>. In contrast, NT<sub>8-13</sub> does not penetrate the receptor as deeply, with the C-terminus of NT<sub>8-13</sub> over 5 Å closer to the extracellular surface than the hydroxyl groups in isoprenaline and adenosine that are characteristic of agonists for  $\beta$ ARs and A<sub>2A</sub>AR. This suggests that the mode of activation of NTS1 is subtly different from these receptors. Structures of NTS1 in the inactive state will be necessary to gain a better understanding of how peptide agonists activate GPCRs.

## Methods summary

The stabilized NTS1 mutant with T4 lysozyme replacing most of intracellular loop 3 was expressed in insect cells and purified by cobalt affinity chromatography. It was crystallized in lipidic cubic phase. Diffraction data were collected at the GM/CA-CAT beamline of the Advanced Photon Source at the Argonne National Laboratory. The structure was solved by molecular replacement using data from a single crystal.

Full Methods and any associated references are available in the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

## Methods

### Materials

The tritiated agonist [<sup>3</sup>H]NT ([3,11-tyrosyl-3,5-3H(N)]-pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) was purchased from Perkin Elmer. Unlabeled NT and NT<sub>8-13</sub> (Arg-Arg-Pro-Tyr-Ile-Leu) were synthesized by the Center for Biologics Evaluation and Research (Food and Drug Administration) or purchased from AnaSpec. The detergents n-dodecyl-β-D-maltopyranoside (DDM), n-decyl-β-D-maltopyranoside (DM), lauryl maltose neopentyl glycol (2,2-didecylpropane-1,3-bis-β-D-maltopyranoside) (LMNG)<sup>44</sup>, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonic acid (CHAPS) and cholesteryl hemisuccinate Tris salt (CHS) were obtained from Anatrace. TCEP was also from Anatrace. Monoolein (M-7765), cholesterol (C-75209), lysozyme (L-6876) and DNaseI (D-4527) were purchased from Sigma. Talon resin was from Clontech. BioSpin-30 Tris columns were obtained from BioRad. PD10 columns were purchased from GE Healthcare.

### Expression of NTS1 in insect cells

The baculovirus construct NTS1-GW5-T4L consisted of the hemagglutinin signal peptide and the Flag tag<sup>45</sup>, followed by the thermostabilized rat NTS1 (T43-K396 containing the mutations A86L, E166A, G215A, L310A, F358A, V360A) with the ICL3 residues H269-R299 replaced by the cysteine-free bacteriophage T4 lysozyme (N2-Y161 with the mutations C54T and C97A) and a GSGS linker. A deca-histidine tag was placed at the C-terminus. NTS1-GW5 contained the wild-type ICL3 sequence. Wild-type NTS1 (Met-T43-Y424) started at T43 but did not contain any other modifications. Recombinant baculoviruses were generated using a modified pFastBac1 transfer plasmid (Invitrogen). *Trichoplusia ni* cells were infected at a cell density of 0.8-1 million cells/ml with recombinant virus at a multiplicity of infection (MOI) of 5, and the temperature was lowered from 28°C to 21°C. Cells were harvested by centrifugation 48 hours post infection, resuspended in hypotonic buffer (10 mM Hepes pH 7.5, 10 mM MgCl<sub>2</sub>, 20 mM KCl), flash-frozen in liquid nitrogen and stored at -80°C until use.

### Preparation of urea-washed P2 insect cell membranes

NTS1-enriched membranes were obtained as a P2 fraction from insect cells<sup>46,47</sup>. Prior to G protein coupling assays and agonist binding experiments, the P2 membranes were treated with urea to remove peripherally bound membrane proteins<sup>48,49</sup>. The receptor density in urea-washed P2 membranes was determined by [<sup>3</sup>H]NT saturation binding analysis<sup>47</sup>.

### Stability tests in detergent solution

Cell pellets from 10 ml of insect cell cultures (NTS1-GW5-T4L; cell density at harvest ~1.5-2.5 million cells/ml with ~10 million receptors/cell) or P2 membranes (wild-type NTS1) were resuspended in 2 ml buffer containing DM or LMNG/CHS to give a final buffer composition of 50 mM TrisHCl pH 7.4, 200 mM NaCl, 1% DM or 1% LMNG / 0.1% CHS. The samples were placed on a rotating mixer at 4°C for 1 hour. Cell debris and non-solubilized material were removed by ultracentrifugation (TL120.2 rotor, 60k rpm, 4°C, 30 min in Optima Max bench-top ultracentrifuge, Beckman), and the supernatants containing

detergent-solubilized NTS1 were used to test for thermal stability in the +NT format<sup>47</sup>. For thermal denaturation curves, the supernatants were diluted 6.67-fold into assay buffer (50 mM TrisHCl pH 7.4, 200 mM NaCl) containing 10 nM [<sup>3</sup>H]NT and incubated for 1-2.5 hrs on ice to allow [<sup>3</sup>H]NT binding to NTS1. Samples (120 µl aliquots) were exposed to different temperatures between 0°C and 70°C for 30 min and placed on ice. Separation of receptor-ligand complex from free ligand (100 µl) was achieved by centrifugation-assisted gel filtration (spin assay) using Bio-Spin 30 Tris columns, equilibrated with RDB buffer (50 mM TrisHCl pH 7.4, 1 mM EDTA, 0.1% DDM, 0.2% CHAPS, 0.04% CHS). Control reactions on ice were recorded at the start and at the end of each denaturation experiment. The percentage of activity remaining after heat exposure was determined with respect to the unheated control. Data were analyzed by nonlinear regression using a Boltzmann sigmoidal equation in the Prism software (GraphPad).

### Ligand binding experiments

All radio-ligand binding assays were conducted with urea-washed P2 insect cell membranes containing wild-type NTS1, NTS1-GW5-T4L or NTS1-GW5.

For agonist [<sup>3</sup>H]NT saturation binding experiments, receptors were incubated on ice for 1 hour in 250 µl TEBB buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% BSA, 0.004% bacitracin) containing [<sup>3</sup>H]NT at a concentration of 0.6-20 nM. Nonspecific [<sup>3</sup>H]NT binding was determined in the presence of 50 µM unlabeled NT. Separation of bound from free ligand was achieved by rapid filtration through GF/B glass fiber filters (Whatman) pretreated with polyethylenimine. The amount of radioactivity was quantified by liquid scintillation counting (Beckman LS6500). Data were analyzed by nonlinear regression using the GraphPad Prism software and best fit to a one-site binding equation to determine the equilibrium dissociation constant ( $K_d$ ) for wild-type NTS1 / “apparent” dissociation constants for NTS1-GW5-T4L and NTS1-GW5. Note that the saturation binding experiments using wild-type NTS1 were conducted at equilibrium. In contrast, binding of [<sup>3</sup>H]NT to NTS1-GW5-T4L and NTS1-GW5 did not reach equilibrium within the incubation time because of the very slow agonist off-rates.

Competition assays with the non-peptide antagonist SR48692 (ref.<sup>50</sup>) were performed in the presence of [<sup>3</sup>H]NT (TEBB buffer, 5 nM [<sup>3</sup>H]NT, NTS1 concentration < 0.5 nM, incubation for 2 hours on ice, 250 µl assay volume). Data were fit to a sigmoidal dose-response equation with standard slope using the concentrations of total SR48692 added versus bound [<sup>3</sup>H]NT.

The effect of Na<sup>+</sup> ions on [<sup>3</sup>H]NT binding was measured with NaCl concentrations ranging from 0 to 1 M (TEBB buffer, 8 nM [<sup>3</sup>H]NT, NTS1 concentration < 0.5 nM, incubation for 1.5 hours on ice, 300 µl assay volume). Data were analyzed by nonlinear regression using the GraphPad Prism four-parameter dose-response equation (variable slope) with the top and bottom plateaux constrained from 100%-15% (wild-type NTS1) and 100%-50% (NTS1-GW5-T4L, NTS1-GW5), respectively.

The association of [<sup>3</sup>H]NT was assessed at a concentration of 10 nM (TEBB buffer, NTS1 concentration < 0.5 nM). At the indicated time points, 250 µl aliquots were filtered over



glass fiber filters. After 2 hours, [<sup>3</sup>H]NT dissociation was initiated by adding 41.7 μM unlabeled NT or by addition of 41.7 μM NT and 833 mM NaCl; this step reduced the concentration of [<sup>3</sup>H]NT to 8 nM. Samples were subjected to filtration after the indicated time points. No attempt was made to quantitatively compare the observed rates of association and the dissociation rate constants between NTS1 constructs because of the very fast association of agonist to wild-type NTS1, the very fast dissociation of agonist from wild-type NTS1 in the presence of NaCl, and the very slow dissociation of [<sup>3</sup>H]NT from NTS1-GW5-T4L and NTS1-GW5.

### GTPγS assays

Prior to G protein coupling assays, the P2 membranes were treated with urea to remove peripherally bound membrane proteins<sup>48,49</sup>. GDP/[<sup>35</sup>S]GTPγS exchange assays were performed as previously described<sup>47</sup> with 1 nM receptor, 100 nM Gaq (purified from dark-adapted *Sepia officinalis* retina<sup>48</sup>), 500 nM Gβ<sub>1</sub>γ<sub>1</sub> (purified from bovine retina<sup>51</sup>), and 10 μM NT, 40 μM nonpeptide antagonist SR48692 (ref.<sup>50</sup>) or no ligand in the reaction (5 min at 30°C).

### Large-scale purification of NTS1-GW5-T4L from insect cell membranes

Cells from 3L of insect cell culture were thawed and the volume was brought to approximately 240 ml with hypotonic buffer (10 mM Hepes pH 7.5, 10 mM MgCl<sub>2</sub>, 20 mM KCl). The cells were then resuspended using a Turrax T-25 (IKA) homogenizer at 8,200 rpm for 2 min. After centrifugation (45Ti rotor, 40,000 rpm, 45 min, 4°C, Optima L90K, Beckman), the membranes were resuspended (Turrax T-25) in approx. 240 ml of high-salt buffer (10 mM Hepes pH 7.5, 1 M NaCl, 10 mM MgCl<sub>2</sub>, 20 mM KCl) supplemented with DNaseI (final concentration 10 μg/ml) and AEBSF (100 μM), and centrifuged again. All subsequent steps were performed at 4°C or on ice, and AEBSF (100 μM final concentration) was repeatedly added throughout the procedure. The washed membranes were resuspended in 60 ml of buffer (100 mM TrisHCl pH 7.4, 60% glycerol) containing 20 μM NT<sub>8-13</sub>, and stirred for 45 min to allow agonist binding to membrane-inserted NTS1-GW5-T4L. The receptor was extracted by drop-wise addition of 40 ml of a 3% LMNG / 0.3% CHS solution. After 1 hour, NaCl was added, and the solution was gently stirred for an additional hour. The final volume was 120 ml containing 50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 1% LMNG / 0.1% CHS and 10 μM NT<sub>8-13</sub>. The sample was clarified by centrifugation (45Ti rotor, 40,000 rpm, 1 hour, Optima L90K, Beckman), adjusted with imidazole to a final concentration of 20 mM, and then passed through a 0.2 μm filter (Stericup). Next, the sample was loaded at a flow rate of 0.2 ml/min onto 2.5 ml Talon resin packed into an XK16 column (GE Healthcare) equilibrated with Talon-A<sup>+</sup> buffer (50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 20 mM imidazole, 1 μM NT<sub>8-13</sub>, 0.1% LMNG / 0.01% CHS). After washing with 29 column volumes of buffer Talon-A<sup>+</sup>, NTS1-GW5-T4L was eluted with Talon-B<sup>+</sup> buffer (50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 200 mM imidazole, 5 μM NT<sub>8-13</sub>, 0.1% LMNG / 0.01% CHS). Peak fractions were collected (5 ml) and desalted using PD10 columns equilibrated in PD10 buffer (20 mM TrisHCl pH 7.4, 100 mM NaCl, 0.003% LMNG / 0.0003% CHS). NT<sub>8-13</sub> was then added to a concentration of 10 μM, and the sample was used for crystallization. Three liters of insect cell culture yielded ~1.7 mg of purified NTS1-GW5-T4L.

## Crystallization

Purified desalted NTS1-GW5-T4L was diluted 4-fold into buffer (25 mM TrisHCl pH 7.4, 100 mM NaCl) containing 100  $\mu$ M TCEP and then concentrated to an estimated 20-25 mg/ml using a 100,000 MWCO concentrator (Amicon Ultra, Millipore). After addition of NT<sub>8-13</sub> to 1 mM and centrifugation (TLA 120.1 rotor, 60,000 rpm, 15 min, 8°C, Beckman), the sample was mixed with 1.5 parts by weight of a mix of monoolein with cholesterol (10:1) using the two-syringe method<sup>52</sup>. The resulting lipidic cubic phase<sup>53</sup> mix was dispensed in 65 nl drops onto Laminex plates (Molecular Dimensions) and overlaid with 750 nl precipitant solution. Crystals grew after one week in precipitant solution consisting of 20.8% PEG 400, 80 mM Hepes pH 7.0, 2 mM TCEP and 43 mM NaK tartrate. Crystals were harvested directly from LCP using 50  $\mu$ m micro-loops (M5-L18SP-50, MiTeGen) and immediately flash frozen in liquid nitrogen without adding extra cryoprotectant.

## Data collection and structure determination

Data collection was performed with the JBluIce-EPICS data acquisition software at the GM/CA-CAT (23-ID-B) beamline at the Advanced Photon Source of Argonne National Laboratory. Crystals within the loop were located by diffraction using the automated rastering module of JBluIce-EPICS<sup>54,55</sup>. Most crystals showed diffraction spots to ~4-5 Å; a few crystals diffracted to ~3-3.5 Å with a single crystal showing diffraction to ~2.6 Å. A single dataset was collected from this crystal containing 150 frames with an oscillation of 1 degree/frame and was processed in space group P2<sub>1</sub> to 2.80 Å with an overall completeness of 93.1%.

Structure determination was performed by molecular replacement using the Phaser-MR module of PHENIX<sup>56</sup>. Two search models were created using the structure of  $\beta_2$ AR<sup>57</sup> (PDB code 3NY9) with one containing the T4 lysozyme domain and one containing the receptor seven-helix bundle without side chains. One copy of each search model was found, producing a single solution. Subsequent refinement was performed by PHENIX<sup>56</sup> and model building with COOT<sup>58</sup>. Strong difference density was observed within the ligand binding cavity which we were able to model unambiguously as the six residue neurotensin peptide RRPYIL (NT<sub>8-13</sub>). The structure was refined with final R/R<sub>free</sub> values of 0.23/0.28. A summary of data collection and refinement statistics is reported in Supplementary Table S3.

We noted during the later stages of structure determination that no electron density was observed for the C-terminal carboxyl group of NT<sub>8-13</sub> (using an F<sub>o</sub>-F<sub>c</sub> map contoured at ~0.1 e<sup>-</sup>/Å<sup>3</sup>, ~2  $\sigma$ ) despite clear electron density for the rest of the agonist peptide. However, relatively strong density was found in close proximity to the modeled C-terminal carboxyl group of L13 (Fig. S12). We interpreted the lack of density for the modeled C-terminal carboxyl group of NT<sub>8-13</sub> and the presence of electron density close by as a likely result of decarboxylation caused by radiation damage<sup>59,60</sup> (estimated absorbed dose over 150 frames ~314 MGy, 10x experimental dose limit, RADDPOSE<sup>61</sup>) with the cleaved entity being stabilized by a potential salt-bridge like interaction with R327. However, for the purpose of understanding the biology and the interactions involved in agonist binding by NTS1 *in vivo* *i.e.* in the absence of radiation damage, and to minimize any confusion for those scientists who may not be familiar with x-ray crystallography yet who may view the NTS1-GW5-T4L

structure, we have chosen to model NT<sub>8-13</sub> with a carboxyl group at its C-terminus in the final NTS1-GW5-T4L model.

Figures were prepared in PyMOL (Schrödinger). Structural alignments were done with the 'align' command of PyMOL.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

This research was supported by the Intramural Research Program of the National Institutes of Health (JFW, JG-J, PS, RG: National Institute of Neurological Disorders and Stroke; NN, JS: National Institute of Diabetes and Digestive and Kidney Diseases) and a joint grant from Pfizer Global Research and Development and the MRCT Development Gap Fund in addition to core funding from the UK Medical Research Council MRC U105197215 (YS, CGT). The Protein Production Facility of the New York Consortium on Membrane Protein Structure was supported by the National Institutes of Health grant U54GM075026 (JL, BK). We thank the staff at the General Medicine and Cancer Institute's Collaborative Access Team (GM/CA-CAT) beamline at the Advanced Photon Source, Argonne National Laboratory for their assistance during data collection. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract No. DE-AC02-06CH11357.

## Abbreviations

<b>AEBSF</b>	4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride
<b>CHAPS</b>	3-[(3-cholamidopropyl)dimethylammonio]propanesulfonic acid
<b>CHS</b>	cholesteryl hemisuccinate Tris salt
<b>DDM</b>	n-dodecyl- $\beta$ -D-maltopyranoside
<b>DM</b>	n-decyl- $\beta$ -D-maltopyranoside
<b>EDTA</b>	ethylenediaminetetraacetic acid
<b>ICL</b>	intracellular loop
<b>LMNG</b>	lauryl maltose neopentyl glycol (2,2-didecylpropane-1,3-bis- $\beta$ -D-maltopyranoside)
<b>T4L</b>	cysteine-free bacteriophage T4 lysozyme (C54T, C97A)
<b>TCEP</b>	Tris (2-carboxyethyl) phosphine hydrochloride


## References

1. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. *J. Biol. Chem.* 1973; 248:6854–6861. [PubMed: 4745447]
2. Bissette G, Nemeroff CB, Loosen PT, Prange AJ Jr, Lipton MA. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. *Nature.* 1976; 262:607–609. [PubMed: 8728]
3. Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. *Peptides.* 2006; 27:2445–2460. [PubMed: 16887236]
4. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? *Nat. Rev. Drug Discov.* 2012; 11:462–478. [PubMed: 22596253]


5. Kitabgi P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. *Curr. Opin. Drug Discov. Devel.* 2002; 5:764–776.
6. Schimpff R-M, et al. Increased plasma neurotensin concentrations in patients with Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry.* 2001; 70:784–786. [PubMed: 11385014]
7. Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. *Neuron.* 1990; 4:847–854. [PubMed: 1694443]
8. Chalon P, et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. *FEBS Lett.* 1996; 386:91–94. [PubMed: 8647296]
9. Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? *Cell. Signal.* 2001; 13:1–6. [PubMed: 11257441]
10. Barroso S, et al. Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1. *J. Biol. Chem.* 2000; 275:328–336. [PubMed: 10617622]
11. Härterich S, Koschätzky S, Einsiedel J, Gmeiner P. Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1. *Bioorg. Med. Chem.* 2008; 16:9359–9368. [PubMed: 18809332]
12. Pang YP, Cusack B, Groshan K, Richelson E. Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13). *J. Biol. Chem.* 1996; 271:15060–15068. [PubMed: 8663052]
13. Deupi X, Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. *Curr. Opin. Struct. Biol.* 2011; 21:541–551. [PubMed: 21723721]
14. Katritch V, Cherezov V, Stevens RC. Diversity and modularity of G protein-coupled receptor structures. *Trends Pharmacol. Sci.* 2012; 33:17–27. [PubMed: 22032986]
15. Lebon G, Warne T, Tate CG. Agonist-bound structures of G protein-coupled receptors. *Curr. Opin. Struct. Biol.* 2012; 22:1–9. [PubMed: 22265341]
16. Fredriksson R, Lagerstrom MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol. Pharmacol.* 2003; 63:1256–1272. [PubMed: 12761335]
17. Granier S, et al. Structure of the delta-opioid receptor bound to naltrindole. *Nature.* 2012; 485:400–404. [PubMed: 22596164]
18. Manglik A, et al. Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. *Nature.* 2012; 485:321–326. [PubMed: 22437502]
19. Thompson AA, et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. *Nature.* 2012; 485:395–399. [PubMed: 22596163]
20. Wu H, et al. Structure of the human kappa-opioid receptor in complex with JDTic. *Nature.* 2012; 485:327–332. [PubMed: 22437504]
21. Wu B, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. *Science.* 2010; 330:1066–1071. [PubMed: 20929726]
22. Choe HW, et al. Crystal structure of metarhodopsin II. *Nature.* 2011; 471:651–655. [PubMed: 21389988]
23. Standfuss J, et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. *Nature.* 2011; 471:656–660. [PubMed: 21389983]
24. Lebon G, et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. *Nature.* 2011; 474:521–525. [PubMed: 21593763]
25. Gether U, et al. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. *J. Biol. Chem.* 1997; 272:2587–2590. [PubMed: 9006889]
26. Tate CG. A crystal clear solution for determining GPCR structures. *Trends Biochem. Sci.* 2012; 37:343–352. [PubMed: 22784935]
27. Shibata Y, et al. Thermostabilization of the neurotensin receptor NTS1. *J. Mol. Biol.* 2009; 390:262–277. [PubMed: 19422831]
28. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods Neurosci.* 1995; 25:366–428.

29. Rosenbaum DM, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. *Science*. 2007; 318:1266–1273. [PubMed: 17962519]
30. Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. *Nat. Protoc*. 2009; 4:706–731. [PubMed: 19390528]
31. Warne T, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. *Nature*. 2008; 454:486–491. [PubMed: 18594507]
32. Rasmussen SG, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature*. 2011; 477:549–555. [PubMed: 21772288]
33. Rasmussen SG, et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. *Nature*. 2011; 469:175–180. [PubMed: 21228869]
34. Barroso S, Richard F, Nicolas-Etheve D, Kitabgi P, Labbe-Jullie C. Constitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in helix seven. *Br. J. Pharmacol*. 2002; 135:997–1002. [PubMed: 11861328]
35. Goncalves JA, et al. Highly conserved tyrosine stabilizes the active state of rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* 2010; 107:19861–19866. [PubMed: 21041664]
36. Vogel R, et al. Functional role of the “ionic lock”—an interhelical hydrogen-bond network in family A heptahelical receptors. *J. Mol. Biol*. 2008; 380:648–655. [PubMed: 18554610]
37. Vita N, et al. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. *FEBS Lett*. 1993; 317:139–142. [PubMed: 8381365]
38. Scheerer P, et al. Crystal structure of opsin in its G-protein-interacting conformation. *Nature*. 2008; 455:497–502. [PubMed: 18818650]
39. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. *J. Mol. Biol*. 2004; 343:1409–1438. [PubMed: 15491621]
40. Cherezov V, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. *Science*. 2007; 318:1258–1265. [PubMed: 17962520]
41. Henry JA, Horwell DC, Meecham KG, Rees DC. A structure-affinity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan. *Bioorg. Med. Chem. Lett*. 1993; 3:949–952.
42. Luca S, et al. The conformation of neurotensin bound to its G protein-coupled receptor. *Proc. Natl. Acad. Sci. U.S.A.* 2003; 100:10706–10711. [PubMed: 12960362]
43. Warne T, et al. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. *Nature*. 2011; 469:241–244. [PubMed: 21228877]
44. Chae PS, et al. Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. *Nat. Methods*. 2010; 7:1003–1008. [PubMed: 21037590]
45. Kobilka BK. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. *Anal. Biochem*. 1995; 231:269–271. [PubMed: 8678314]
46. Hellmich MR, Battey JF, Northup JK. Selective reconstitution of gastrin-releasing peptide receptor with G alpha q. *Proc. Natl. Acad. Sci. U.S.A.* 1997; 94:751–756. [PubMed: 9012857]
47. Shibata Y, et al. Thermostabilization of the neurotensin receptor NTS1. *J. Mol. Biol*. 2009; 390:262–277. [PubMed: 19422831]
48. Hartman JL, Northup JK. Functional reconstitution in situ of 5-hydroxytryptamine 2c (5HT2c) receptors with alphaq and inverse agonism of 5HT2c receptor antagonists. *J. Biol. Chem*. 1996; 271:22591–22597. [PubMed: 8798428]
49. Jian X, et al. The bombesin receptor subtypes have distinct G protein specificities. *J. Biol. Chem*. 1999; 274:11573–11581. [PubMed: 10206964]
50. Gully D, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. *Proc. Natl. Acad. Sci. U.S.A.* 1993; 90:65–69. [PubMed: 8380498]
51. Inagaki S, et al. Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid. *J. Mol. Biol*. 2012; 417:95–111. [PubMed: 22306739]
52. Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. *Nat. Protoc*. 2009; 4:706–731. [PubMed: 19390528]

53. Landau EM, Rosenbusch JP. Lipidic cubic phases: A novel concept for the crystallization of membrane proteins. *Proc. Natl. Acad. Sci. U.S.A.* 1996; 93:14532–14535. [PubMed: 8962086]
54. Cherezov V, et al. Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam. *J. R. Soc. Interface.* 2009; 6(Suppl 5):S587–S597. [PubMed: 19535414]
55. Hilgart MC, et al. Automated sample-scanning methods for radiation damage mitigation and diffraction-based centering of macromolecular crystals. *J. Synchrotron Radiat.* 2011; 18:717–722. [PubMed: 21862850]
56. Adams PD, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 2010; 66:213–221. [PubMed: 20124702]
57. Wacker D, et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. *J. Am. Chem. Soc.* 2010; 132:11443–11445. [PubMed: 20669948]
58. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* 2010; 66:486–501. [PubMed: 20383002]
59. Burmeister WP. Structural changes in a cryo-cooled protein crystal owing to radiation damage. *Acta Crystallogr. D Biol. Crystallogr.* 2000; 56:328–341. [PubMed: 10713520]
60. Weik M, et al. Specific chemical and structural damage to proteins produced by synchrotron radiation. *Proc. Natl. Acad. Sci. U.S.A.* 2000; 97:623–628. [PubMed: 10639129]
61. Paithankar KS, Owen RL, Garman EF. Absorbed dose calculations for macromolecular crystals: improvements to RADDOS. *J. Synchrotron Radiat.* 2009; 16:152–162. [PubMed: 19240327]




**Fig. 1. Overview of the NTS1 structure bound to the peptide agonist NT<sub>8-13</sub>**  
 Cartoon representation of NTS1-GW5-T4L; (a) side view, (b) extracellular view, (c) intracellular view. Space filling models are used to depict the agonist NT<sub>8-13</sub> (orange), the side chains of thermostabilizing mutations (purple) and the disulphide bond (yellow) between the conserved residues C142 and C225. Also shown are the  $\beta$ -hairpin in extracellular loop 2 (blue-green) and the  $\pi$ -helix in intracellular loop 2 (ICL2). T4L has been omitted from the intracellular view for clarity.



**Fig. 2. NTS1-GW5-T4L is in an active-like conformation**


(a) Alignment of NTS1-GW5 (green) with the inactive state of the nociceptin receptor (NOP)<sup>19</sup> (red, PDB code 4EA3). NTS1 was most similar to NOP (root mean squared deviation = 2.1 Å for Ca atoms in the TM domains) upon alignment of the TM domains of NTS1 with other peptide receptors<sup>17-21</sup>. (b) Alignment of the inactive state of rhodopsin<sup>39</sup> (light brown, PDB code 1GZM), its active state Meta-II (ref.<sup>22</sup>) (blue-green, PDB code 3PQR) and NTS1-GW5 (green). (c) Alignment of the inactive state of  $\beta_2$ AR<sup>40</sup> (pale mauve, PDB code 2RH1) and its active state<sup>32</sup> (pale grey, PDB code 3SN6) and NTS1-GW5 (green). All views are from the intracellular surface. The arrows indicate the apparent displacement of TM5 and TM6 of NTS1-GW5 relative to the corresponding helix positions in the inactive receptor structures.






**Fig. 3. The conserved D/ERY and NPxxY motifs in NTS1-GW5**

(a) Comparison of the side chain orientations of R<sup>3.50</sup> and Y/N<sup>5.58</sup> of NTS1-GW5 and the inactive nociceptin receptor (NOP)<sup>19</sup> (PDB code 4EA3). NTS1-GW5 residues (R167, N257, labeled) in green; corresponding NOP residues (R148, Y235, unlabeled) in red. D147<sup>3.49</sup> of NOP and A166<sup>3.49</sup> of NTS1 are also shown. (b) In an inactive GPCR, R<sup>3.50</sup> interacts with E<sup>3.49</sup> as shown here for rhodopsin<sup>39</sup> (pale brown, PDB code 1GZM). This salt bridge is broken upon activation allowing R<sup>3.50</sup> to contact residue<sup>5.58</sup> as depicted for active rhodopsin (ref.<sup>22</sup>) (blue-green, PDB code 3PQR) (residues E134, R135 and Y223). (c) The same comparison for inactive  $\beta_2$ AR<sup>40</sup> (pale mauve, PDB code 2RH1) and active  $\beta_2$ AR<sup>32</sup> (pale grey, PDB code 3SN6) (residues E130, R131 and Y219). (d) Y369<sup>7.53</sup> of NTS1 (green) occupies space as seen for Y306<sup>7.53</sup> in active rhodopsin (blue-green, PDB code 3PQR). The orientation of Y306<sup>7.53</sup> in the inactive rhodopsin (pale brown, PDB code 1GZM) and the inactive NOP (red, PDB code 4EA3) is shown for comparison.



**Fig. 4. The NTS1 agonist binding pocket**

All views are from the extracellular side with NT<sub>8-13</sub> shown as a stick model. (a) Cartoon representation of the ligand binding pocket with the ECL2  $\beta$ -hairpin (pink). The quality of the electron density of NT<sub>8-13</sub> is depicted as blue isosurface ( $2F_o-F_c$  map contoured at  $1\sigma$ ). (b) Key NTS1 residues (green residues with grey labels) in contact with the peptide ligand (grey residues with bold black labels). Hydrogen bonds and salt bridges are indicated by dashed lines (black). The electron density maps of selected NTS1 residues (L55, Y146, T226, R327) are shown as blue isosurface ( $2F_o-F_c$  map contoured at  $1\sigma$ ). (c) The charge complementarity between NT<sub>8-13</sub> and its binding pocket is depicted with the NTS1 surface colored according to its electrostatic potential ( $-4$  kT/e to  $+4$  kT/e; red, negative; blue, positive). The positively charged arginine side chains of the ligand face the electronegative rim of the binding pocket whereas the negatively charged carboxylate of L13 resides in an electropositive environment. See also Supplementary Information.



**Fig. 5. A new paradigm for peptide agonist binding**

Compared to small endogenous agonists, the NT<sub>8-13</sub> binding cavity is located near the receptor surface. (a) The structures of the agonist-bound adenosine A<sub>2A</sub> receptor<sup>24</sup> (PDB ID 2YDO),  $\beta_1$ AR<sup>43</sup> (PDB ID 2Y03) and meta-rhodopsin II (ref.<sup>22</sup>) (PDB code 3PQR) were aligned in PyMOL. Only the cartoon representation for NTS1-GW5 is shown (pale green) with NT<sub>8-13</sub> depicted in purple. The agonists adenosine (blue-green), isoprenaline (yellow; an isopropyl derivative of the endogenous ligand noradrenaline) and all-*trans*-retinal (red) are labeled. The chemical groups in adenosine and isoprenaline that make agonist-specific contacts to the receptor are circled (dashed line). (b) The cyclic antagonist peptide CVX15 binds to the CXCR4 receptor<sup>21</sup> (grey, PDB ID 3OE0) in a similar fashion to NT<sub>8-13</sub> (purple) in NTS1-GW5 (pale green cartoon).